The cost-effectiveness analysis of mavacamten in treating obstructive hypertrophic cardiomyopathy is crucial as it may shape treatment guidelines and reimbursement policies. This could significantly affect market access and competitive positioning for mavacamten within the cardiology landscape. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 10 ranked evidence items (4 high-relevance).